1. Home
  2. ICON vs OGEN Comparison

ICON vs OGEN Comparison

Compare ICON & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$1.02

Market Cap

3.4M

Sector

N/A

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.54

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
OGEN
Founded
2023
1996
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.8M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
ICON
OGEN
Price
$1.02
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.4K
21.0K
Earning Date
02-24-2026
05-11-2026
Dividend Yield
4754.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.33
N/A
Revenue Next Year
$23.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.48
52 Week High
$4.23
$1.45

Technical Indicators

Market Signals
Indicator
ICON
OGEN
Relative Strength Index (RSI) 52.19 50.49
Support Level $0.84 $0.49
Resistance Level $1.20 $0.60
Average True Range (ATR) 0.08 0.03
MACD 0.00 0.01
Stochastic Oscillator 55.17 70.54

Price Performance

Historical Comparison
ICON
OGEN

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: